The pandemic has exacerbated the challenges Pharmaceutical companies face in striving to successfully engage with stakeholders. Covid has reduced time available for commercial engagements, created new issues around patient adherence, increased the claim burden on payers and caused an explosion of digital patient engagement channels. This new norm is driving a transformation in omni-channel capabilities now necessary for Pharmaceutical companies to achieve personalized, cost-effective engagement and generate impact with stakeholders.